Headlines about Novan (NASDAQ:NOVN) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Novan earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave headlines about the company an impact score of 44.1922746500496 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Novan (NOVN) traded down $0.63 during trading on Monday, hitting $5.70. The stock had a trading volume of 114,053 shares, compared to its average volume of 53,818. Novan has a 12 month low of $3.52 and a 12 month high of $30.90.
A number of analysts have recently commented on the company. ValuEngine upgraded Novan from a “strong sell” rating to a “sell” rating in a report on Friday, September 15th. Zacks Investment Research upgraded Novan from a “sell” rating to a “hold” rating in a report on Wednesday, October 4th. Wedbush restated a “neutral” rating and issued a $6.00 price target on shares of Novan in a report on Monday, September 25th. Finally, Piper Jaffray Companies restated a “buy” rating on shares of Novan in a report on Thursday, August 3rd.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://sportsperspectives.com/2017/11/06/novan-novn-getting-somewhat-favorable-news-coverage-report-finds.html.
In other Novan news, Director John W. Palmour bought 12,000 shares of the business’s stock in a transaction dated Wednesday, August 23rd. The shares were acquired at an average cost of $3.99 per share, with a total value of $47,880.00. Following the acquisition, the director now directly owns 253,568 shares of the company’s stock, valued at approximately $1,011,736.32. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Insiders own 10.72% of the company’s stock.
Novan, Inc is a late-stage pharmaceutical company. The Company is engaged in the development and commercialization of therapies using its nitric oxide platform. The Company develops product candidates using its Nitricil technology, which enables the Company to engineer tunable new chemical entities (NCEs).
Receive News & Ratings for Novan Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novan Inc. and related companies with MarketBeat.com's FREE daily email newsletter.